|
JPS509164B1
(enExample)
|
1970-12-29 |
1975-04-10 |
|
|
|
HU190774B
(en)
|
1979-06-29 |
1986-11-28 |
The Wellcome Foundation Ltd,Gb |
Process for preparing ether derivatives with pharmacological activity
|
|
GB2090830B
(en)
|
1980-12-18 |
1984-09-26 |
Wellcome Found |
Formyl ether derivatives
|
|
JPS58167304A
(ja)
|
1982-03-24 |
1983-10-03 |
松下電器産業株式会社 |
ごみ処理装置
|
|
AU576322B2
(en)
|
1983-07-22 |
1988-08-25 |
Ici Australia Limited |
Alpha-substituted-alpha-cyanomethyl alcohols
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
JPH05255106A
(ja)
|
1990-10-31 |
1993-10-05 |
Toray Ind Inc |
血小板減少症治療剤
|
|
JPH059164A
(ja)
|
1991-07-02 |
1993-01-19 |
Sumitomo Chem Co Ltd |
光学活性マンデロニトリル誘導体の製造方法
|
|
GB9217331D0
(en)
|
1992-08-14 |
1992-09-30 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US6096786A
(en)
|
1992-10-01 |
2000-08-01 |
Glaxo Wellcome Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
US5872151A
(en)
|
1992-10-01 |
1999-02-16 |
Glaxo Wellcome Inc. |
Immunopotentiatory agents and physiologically acceptable salts thereof
|
|
ES2096215T3
(es)
|
1992-10-01 |
1997-03-01 |
Wellcome Found |
Tucaresol como agente inmunopotenciador.
|
|
CA2149150C
(en)
|
1992-11-27 |
2000-08-01 |
David R. Carver |
Injectable taxol composition with improved stability
|
|
JPH0725858A
(ja)
|
1993-07-13 |
1995-01-27 |
Otsuka Pharmaceut Co Ltd |
ピペラジン誘導体
|
|
US5958980A
(en)
|
1993-08-26 |
1999-09-28 |
Glaxo Wellcome, Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
GB9402809D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9402807D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9426224D0
(en)
|
1994-12-23 |
1995-02-22 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5891877A
(en)
|
1995-02-14 |
1999-04-06 |
Xenova Limited |
Pharmaceutical compounds
|
|
US5874443A
(en)
|
1995-10-19 |
1999-02-23 |
Trega Biosciences, Inc. |
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
US5886210A
(en)
|
1996-08-22 |
1999-03-23 |
Rohm And Haas Company |
Method for preparing aromatic compounds
|
|
JP3131574B2
(ja)
|
1996-09-04 |
2001-02-05 |
新日本製鐵株式会社 |
新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
|
|
US5939098A
(en)
|
1996-09-19 |
1999-08-17 |
Schering Corporation |
Cancer treatment with temozolomide
|
|
US5922683A
(en)
|
1997-05-29 |
1999-07-13 |
Abbott Laboratories |
Multicyclic erythromycin derivatives
|
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
|
DE69842004D1
(de)
|
1997-11-21 |
2010-12-30 |
Purdue Neuroscience Co |
Substituierte 2-aminoacetamide und anwendung davon
|
|
HUP0101329A3
(en)
|
1998-01-29 |
2002-07-29 |
Aventis Pharmaceuticals Inc Co |
Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
|
|
US7141603B2
(en)
|
1999-02-19 |
2006-11-28 |
The Regents Of The University California |
Antitumor agents
|
|
US6069146A
(en)
|
1998-03-25 |
2000-05-30 |
The Regents Of The University Of California |
Halimide, a cytotoxic marine natural product, and derivatives thereof
|
|
CN1142909C
(zh)
|
1998-03-26 |
2004-03-24 |
盐野义制药株式会社 |
具有抗病毒活性的吲哚衍生物
|
|
US6509331B1
(en)
|
1998-06-22 |
2003-01-21 |
Elan Pharmaceuticals, Inc. |
Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
|
|
GB9818627D0
(en)
|
1998-08-26 |
1998-10-21 |
Glaxo Group Ltd |
Improvements in dva vaccination
|
|
FR2784988B1
(fr)
|
1998-10-23 |
2002-09-20 |
Adir |
Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US7026322B2
(en)
|
1998-11-12 |
2006-04-11 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
US6358957B1
(en)
|
1998-11-12 |
2002-03-19 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
CA2383424C
(en)
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Novel b7-4 molecules and uses therefor
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
JP4810043B2
(ja)
|
2000-01-18 |
2011-11-09 |
ネリアス・ファーマシュティカルズ・インコーポレーテッド |
細胞分裂阻害剤及びその製造方法
|
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
|
HUP0302358A3
(en)
|
2000-05-09 |
2007-09-28 |
Adpharma |
Piperazinedione compounds and use of them for producing pharmaceutical compositions
|
|
EP1345938A1
(en)
|
2000-12-28 |
2003-09-24 |
Neurocrine Biosciences, Inc. |
Tricyclic crf receptor antagonists
|
|
US20030082140A1
(en)
|
2001-08-20 |
2003-05-01 |
Fisher Paul B. |
Combinatorial methods for inducing cancer cell death
|
|
US20040176372A1
(en)
|
2002-03-01 |
2004-09-09 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
RU2321396C2
(ru)
*
|
2002-05-17 |
2008-04-10 |
Авентис Фарма С.А. |
Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
US7935704B2
(en)
|
2003-08-01 |
2011-05-03 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
DK1529044T5
(da)
|
2002-08-02 |
2008-04-21 |
Nereus Pharmaceuticals Inc |
Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
|
|
US7919497B2
(en)
|
2002-08-02 |
2011-04-05 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
JP2007520565A
(ja)
|
2004-02-04 |
2007-07-26 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
|
|
HRP20160757T1
(hr)
|
2004-04-19 |
2016-08-12 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata
|
|
DE202004018940U1
(de)
|
2004-12-07 |
2006-04-13 |
Asf Verwaltungs Gmbh |
Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
WO2007035841A1
(en)
|
2005-09-21 |
2007-03-29 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
EP1973569B1
(en)
|
2006-01-18 |
2013-05-22 |
Merck Patent GmbH |
Specific therapy using integrin ligands for treating cancer
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US8129527B2
(en)
|
2006-11-03 |
2012-03-06 |
Nereus Pharmacuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
CN101657213B
(zh)
|
2007-02-15 |
2014-02-26 |
曼康公司 |
用于增强t细胞应答的方法
|
|
CN101678078B
(zh)
|
2007-04-13 |
2014-12-10 |
阿布拉西斯生物科学公司 |
Sparc及其使用方法
|
|
US20090170837A1
(en)
|
2007-08-17 |
2009-07-02 |
Thallion Pharmaceuticals Inc. |
Methods for treating ras driven cancer in a subject
|
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
|
CA2705417A1
(en)
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
|
ES2558568T3
(es)
|
2008-01-08 |
2016-02-05 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
CA2749786A1
(en)
|
2009-01-16 |
2010-07-22 |
Jason Benjamin Bock |
New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
|
|
EP2403539A2
(en)
|
2009-03-02 |
2012-01-11 |
Massachusetts Institute of Technology |
Methods and systems for treatment and/or diagnosis
|
|
WO2010114922A1
(en)
|
2009-03-31 |
2010-10-07 |
Agios Pharmaceuticals, Inc. |
Methods of treating cancer having an aberrant egfr or kras genotype
|
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
|
ES2543280T3
(es)
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
US20120114658A1
(en)
|
2009-09-15 |
2012-05-10 |
John Ryan |
Treatment of cancer
|
|
WO2011034954A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
Treatment of cancer
|
|
US20110274723A1
(en)
|
2009-10-23 |
2011-11-10 |
Mannkind Corporation |
Cancer immunotherapy and method of treatment
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
CN101766815B
(zh)
|
2009-12-31 |
2012-04-25 |
胡松华 |
紫杉醇及多西紫杉醇的用途
|
|
WO2011109625A1
(en)
|
2010-03-03 |
2011-09-09 |
Targeted Molecular Diagnostics, Llc |
Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
|
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
CA2799653A1
(en)
|
2010-06-04 |
2011-12-08 |
Bertrand Leblond |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
|
JP2012033526A
(ja)
|
2010-07-28 |
2012-02-16 |
Fuji Electric Co Ltd |
薄膜太陽電池およびその製造方法
|
|
WO2012035436A1
(en)
|
2010-09-15 |
2012-03-22 |
Tokyo University Of Pharmacy And Life Sciences |
Plinabulin prodrug analogs and therapeutic uses thereof
|
|
WO2012074904A2
(en)
|
2010-11-29 |
2012-06-07 |
Precision Therapeutics, Inc. |
Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
|
|
TWI386203B
(zh)
|
2011-01-07 |
2013-02-21 |
Univ China Medical |
治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
AU2012344676A1
(en)
|
2011-11-28 |
2014-06-19 |
National Research Council Of Canada |
Paclitaxel response markers for cancer
|
|
WO2013090552A1
(en)
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
WO2013124867A1
(en)
|
2012-02-21 |
2013-08-29 |
Amrita Vishwa Vidyapeetham University |
Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
|
|
KR102165348B1
(ko)
|
2012-05-09 |
2020-10-14 |
캔텍스 파마슈티칼즈, 인크. |
골수억제의 치료
|
|
AU2013204313C1
(en)
|
2012-06-01 |
2016-04-07 |
Bionomics Limited |
Combination Therapy
|
|
WO2014036412A2
(en)
|
2012-08-30 |
2014-03-06 |
Amgen Inc. |
A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
|
|
MX369999B
(es)
*
|
2012-10-04 |
2019-11-28 |
Ab Science |
Uso de masitinib en combinación con gemcitabina para el tratamiento de cáncer pancreatico en subpoblaciones de pacientes identificados en base al factor predictor de la intensidad de dolor.
|
|
EP2911669B1
(en)
|
2012-10-26 |
2024-04-10 |
The University of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
WO2014160183A1
(en)
|
2013-03-13 |
2014-10-02 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
TWI614041B
(zh)
|
2013-03-15 |
2018-02-11 |
安美基公司 |
用於注射器之匣盒
|
|
EP2988668B1
(en)
|
2013-04-24 |
2019-07-24 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
HK1216231A1
(zh)
|
2013-06-03 |
2016-10-28 |
Novartis Ag |
Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
|
|
JP6205192B2
(ja)
|
2013-07-02 |
2017-09-27 |
テルモ株式会社 |
薬液充填済み容器体を収容した包装体
|
|
HRP20251187T1
(hr)
*
|
2013-07-12 |
2025-11-21 |
Areteia Therapeutics, Inc. |
Liječenje povišenih razina eozinofila i/ili bazofila
|
|
JP6311097B2
(ja)
|
2013-07-31 |
2018-04-18 |
学校法人東京薬科大学 |
微小管脱重合剤
|
|
ES2902665T3
(es)
*
|
2013-10-11 |
2022-03-29 |
Beyondspring Inc |
Tratamiento del cáncer con combinación de plinabulina y taxano
|
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
CN106232831B
(zh)
|
2013-11-06 |
2021-02-26 |
美国卫生和人力服务部 |
通过表达谱分析对淋巴瘤类型进行亚型分类的方法
|
|
CN104796448B
(zh)
|
2014-01-22 |
2019-02-12 |
腾讯科技（深圳）有限公司 |
网络系统的数据处理方法和装置
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
US10238630B2
(en)
|
2014-05-28 |
2019-03-26 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
|
|
US10392444B2
(en)
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
IL286282B2
(en)
|
2015-02-12 |
2023-10-01 |
Beyondspring Pharmaceuticals Inc |
Use of palinabolin in combination with immune checkpoint inhibitors
|
|
US20250073230A1
(en)
|
2015-02-12 |
2025-03-06 |
Beyondspring Pharmaceuticals, Inc. |
Use of plinabulin in combination with immune checkpoint inhibitors
|
|
HK1249052A1
(zh)
|
2015-03-06 |
2018-10-26 |
BeyondSpring Pharmaceuticals Inc. |
治疗与ras突变相关的癌症的方法
|
|
EP3265091A4
(en)
|
2015-03-06 |
2018-08-01 |
Beyondspring Pharmaceuticals Inc. |
Method of treating a brain tumor
|
|
WO2016165007A1
(en)
|
2015-04-17 |
2016-10-20 |
The University Of British Columbia |
Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
|
|
CN106279039B
(zh)
|
2015-06-02 |
2019-01-11 |
青岛海洋生物医药研究院股份有限公司 |
氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
|
|
MX376122B
(es)
|
2015-07-13 |
2025-03-07 |
Beyondspring Pharmaceuticals Inc |
Composiciones de plinabulina.
|
|
CA2996426A1
(en)
|
2015-10-05 |
2017-04-13 |
Cedars-Sinai Medical Center |
Method of classifying and diagnosing cancer
|
|
SG11201806583XA
(en)
|
2016-02-08 |
2018-09-27 |
Beyondspring Pharmaceuticals Inc |
Compositions containing tucaresol or its analogs
|
|
BR112018074990A2
(pt)
*
|
2016-06-06 |
2019-03-12 |
Beyondspring Pharmaceuticals, Inc. |
composição, usos e método para reduzir neutropenia
|
|
JP6779517B2
(ja)
|
2016-09-02 |
2020-11-04 |
国立大学法人 鹿児島大学 |
抗癌剤の感受性及び癌の予後に対する診断マーカー
|
|
US11633393B2
(en)
|
2017-01-06 |
2023-04-25 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
EP3576733A4
(en)
|
2017-02-01 |
2020-11-25 |
Beyondspring Pharmaceuticals, Inc. |
NEUTROPENIA REDUCTION METHOD
|
|
BR112019018880A2
(pt)
|
2017-03-13 |
2020-04-14 |
Beyondspring Pharmaceuticals Inc |
composições de plinabulina e seu uso
|
|
WO2019126739A1
(en)
|
2017-12-21 |
2019-06-27 |
Shepherd Therapeutics, Inc. |
Pyrvinium pamoate anti-cancer therapies
|
|
KR20200112881A
(ko)
|
2018-01-24 |
2020-10-05 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
|
|
CN112105363A
(zh)
|
2018-02-01 |
2020-12-18 |
大连万春布林医药有限公司 |
用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
|
|
CN110240592A
(zh)
|
2018-03-08 |
2019-09-17 |
青岛海洋生物医药研究院股份有限公司 |
(z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
|
|
US11590130B2
(en)
|
2018-04-05 |
2023-02-28 |
Noviga Research Ab |
Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
|
|
US20210161888A1
(en)
|
2018-06-01 |
2021-06-03 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method of treating cancer associated with egfr mutation
|
|
JP2021534183A
(ja)
|
2018-08-16 |
2021-12-09 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
免疫応答を刺激するための方法及び組成物
|
|
JP2022513038A
(ja)
|
2018-11-14 |
2022-02-07 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
チューブリン結合薬を使用する癌の治療方法
|
|
US20240299377A1
(en)
|
2019-10-15 |
2024-09-12 |
Beyondspring Pharmaceuticals, Inc. |
Methods and compositions for treating iron disorders
|
|
CN112778155B
(zh)
|
2019-11-11 |
2023-08-11 |
大连万春布林医药有限公司 |
妥卡雷琐衍生物及其用途
|
|
MX2022013808A
(es)
|
2020-05-04 |
2023-02-09 |
Beyondspring Pharmaceuticals Inc |
Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
|
|
EP4319751A4
(en)
|
2021-04-09 |
2025-02-26 |
Beyondspring Pharmaceuticals, Inc. |
THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
|
|
CN115703763A
(zh)
|
2021-08-13 |
2023-02-17 |
大连万春布林医药有限公司 |
普那布林或其制剂中的杂质及其用途
|
|
WO2023060200A1
(en)
|
2021-10-07 |
2023-04-13 |
Beyondspring Pharmaceuticals, Inc. |
Methods for treating cancers and tumors
|